Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma

References

• Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533–43
   PubMed Web of Science ®Google Scholar
• Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999; 353: 1253–7
   PubMed Web of Science ®Google Scholar
• Seow, WK, Chia, KS, Shi, LM, Lee, HP, Shanmugaratnam, K. Trends in cancer incidence in Singapore 1968–2002. Singapore Cancer Registry. 2004; Report No. 6.
   Google Scholar
• Ikeda K, Saitoh S, Tsubota A, Arase Y, Chayama K, Kumada H, et al. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 1993; 71: 19–25
   PubMed Web of Science ®Google Scholar
• Levin B, Amos C. Therapy of unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1294–6
   PubMed Web of Science ®Google Scholar
• CLIP Group (Cancer of the Liver Italian Programme). Tamoxifen in treatment of hepatocellular carcinoma: A randomised controlled trial. Lancet 1998; 352: 17–20
   PubMedGoogle Scholar
• Perrone F, Gallo C, Daniele B, Gaeta GB, Izzo F, Capuano G, et al. Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial. Curr Pharm Des 2002; 8: 1013–9
   PubMedGoogle Scholar
• Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: A randomized controlled trial. Hepatology 1993; 17: 389–94
   PubMed Web of Science ®Google Scholar
• Venook AP. Hepatocellular carcinoma. Curr Treat Options Oncol 2000; 1: 407–15
   PubMedGoogle Scholar
• Hsu PI, Chow NH, Lai KH, Yang HB, Chan SH, Lin XZ, et al. Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma. Anticancer Res 1997; 17: 2803–9
   PubMed Web of Science ®Google Scholar
• Yoshida T, Kaneko Y, Tsukamoto A, Han K, Ichinose M, Kimura S. Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP470: Possible involvement of nitric oxide synthase. Cancer Res 1998; 58: 3751–6
   PubMed Web of Science ®Google Scholar
• Zhang ZL, Liu ZS, Sun Q. Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. World J Gastroenterol 2005; 11: 216–20
   PubMedGoogle Scholar
• Kumar S, Witzig TE, Rajkumar SV. Thalidomide as an anti-cancer agent. J Cell Mol Med 2002; 6: 160–74
   PubMed Web of Science ®Google Scholar
• D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082–5
   PubMed Web of Science ®Google Scholar
• Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003; 65: 242–9
   PubMed Web of Science ®Google Scholar
• Wang TE, Kao CR, Lin SC, Chang WH, Chu CH, Lin J, et al. Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 2004; 10: 649–53
   PubMedGoogle Scholar
• Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock TI, et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005; 103: 119–25
   PubMedGoogle Scholar
• Patt YZ, Hassan MM, Lozano RD, Nooka AK, Schnirer II, Zeldis JB, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: A phase II trial. Cancer 2005; 103: 749–55
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
   PubMed Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1–10
   PubMedGoogle Scholar
• Giantonio, BJ, Meropol, NJ, O'Dwyer, PJ, Mitchell, EP, Alberts, SR, Schwartz, MA, Benson, AB. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Prog Proc Am Soc Clin Oncol 2005;2, abstract
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42
   PubMed Web of Science ®Google Scholar
• Lin MI, Sessa WC. Antiangiogenic therapy: Creating a unique “window” of opportunity. Cancer Cell 2004; 6: 529–31
   PubMedGoogle Scholar
• Ng SS, Figg WD. Upregulation of endogenous angiogenesis inhibitors: A mechanism of action of metronomic chemotherapy. Cancer Biol Ther 2004; 3: 1212–3
   PubMed Web of Science ®Google Scholar
• Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000; 23: 319–21
   PubMed Web of Science ®Google Scholar